Freeze All on Oocyte Maturatin by Gonadotropin Agonist Versus Human Chorionic Gonadotroipin
NCT ID: NCT04749979
Last Updated: 2021-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2021-02-05
2021-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles
NCT03209687
Effect of Estradiol Pretreatment on Antagonist ICSI Cycles
NCT05197374
Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day
NCT02397551
Triggering of Follicular Maturation
NCT02916173
Antagonist Protocol in IVF
NCT02335736
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
giving agonist ( eg. decapeptyl )
Giving women agonist
Agonist (decapeptyl )
giving agonist
Giving HCG (eg. choriomon )
Giving women HCG
HCG ( eg. Choriomon )
giving HCG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Agonist (decapeptyl )
giving agonist
HCG ( eg. Choriomon )
giving HCG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female age between 20 and 40 years.
* Primary or secondary infertility.
* Body mass index (BMI) between 18 and 40 kg/m2.
Exclusion Criteria
* Ovarian cysts before induction.
* Known uncontrolled endocrinal abnormalities (like hypo or hyperthyroidism)
18 Years
42 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Aljazeera Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mahmoud Alalfy, PhD
Role: PRINCIPAL_INVESTIGATOR
Algezeera hospitaland National Research Centre ,Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aljazeera( Al Gazeera) hospital
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Oocyte
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.